SCHEMBL5733209

SCHEMBL5733209

Cc1cc(C)c(C(=O)Nc2nccs2)c(C)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.61
RAB9A P51151 8/20 0.61
SMN1; SMN2 Q16637 6/20 0.61
PPARG P37231 1/20 0.61
NCOR2 Q9Y618 1/20 0.61
ALDH1A1 P00352 5/20 0.56
KMT2A Q03164 3/20 0.56
POLB P06746 2/20 0.56
MEN1 O00255 2/20 0.56
AHR P35869 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.55
MAPT P10636 2/20 0.55
KDM4E B2RXH2 1/20 0.55
BLM P54132 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
TSHR P16473 1/20 0.52
LMNA P02545 1/20 0.51
METAP2 P50579 1/20 0.51
METAP1 P53582 1/20 0.51
BRD4 O60885 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16073053 0.85 NPC1 (0.58) NPC1RAB9ASMN1; SMN2PPARGNCOR2
SCHEMBL16073042 0.85 NPC1 (0.58) NPC1RAB9ASMN1; SMN2PPARGNCOR2
SCHEMBL16073043 0.84 NPC1 (0.66) NPC1RAB9ASMN1; SMN2PPARGNCOR2
SCHEMBL14018616 0.83 RAB9A (0.72) NPC1RAB9ASMN1; SMN2PPARGNCOR2
SCHEMBL16073054 0.81 NPC1 (0.69) NPC1RAB9ASMN1; SMN2PPARGNCOR2
SCHEMBL2656790 0.77 NPC1 (0.61) NPC1RAB9ASMN1; SMN2PPARGNCOR2
SCHEMBL3900518 0.77 RAB9A (0.64) NPC1RAB9ASMN1; SMN2PPARGNCOR2
SCHEMBL27924845 0.76 NPC1 (1.00) NPC1RAB9ASMN1; SMN2PPARGNCOR2
SCHEMBL3223685 0.76 RAB9A (1.00) NPC1RAB9ASMN1; SMN2PPARGNCOR2
SCHEMBL4299674 0.76 RAB9A (0.62) NPC1RAB9ASMN1; SMN2PPARGNCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680431-A1 BENZOTHIAZOLE AND THIAZOLE'5,5-B!PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2006-07-19 EP claimed
US-20050130974-A1 Benzothiazole compositions and their use as ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. 2005-06-16 US claimed
WO-2005037845-A1 BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2005-04-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130974-A1 Benzothiazole compositions and their use as ubiquitin ligase inhibitors UBQLN1, UBE2T, NEDD4 NPC1 1713/4885RAB9A 3792/4885SMN1; SMN2 3684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.